Study S001814

A Multicenter, Randomized, Open-label, and Parallel Assignment Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in Combination With Metformin in the Treatment of Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT05816057
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 476
Start: 2022-07-25
Primary completion: 2023-07-25
Lead sponsor: Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:semaglutide injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment. [32 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.